NEW YORK (GenomeWeb News) – PrimeraDx has landed a grant from the National Cancer Institute to develop a gene expression profiling assay that can rapidly detect diffuse large B-Cell lymphoma (DLBCL) subgroups, making it easier to diagnose the disease, select treatment options, and predict the likelihood of patient response to therapy and survival.

The company will use the $335,186 grant, funded under the Innovative Molecular Analysis Technologies Program, to develop the assay on its ICEPlex PCR-based platform, which uses formalin-fixed, paraffin-embedded specimens.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.